

Latham & Watkins Advises Second Genome in \$42.6 Million Series B Financing

News

Second Genome, Inc., a privately-held biopharmaceutical company developing novel medicines through innovative microbiome science, has closed an oversubscribed Series B investment round with \$42.6 million in financing.